Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies / K. Podar and K.C. Anderson
Research on the formation of new blood vessels (angiogenesis) in general and vascular endothelial growth factor (VEGF) in particular is a major focus in biomedicine and has led to the clinical approval of the monoclonal anti- VEGF antibody bevazicumab; and the second-generation multitargeted receptor kinase inhibitors (RTKIs) sorafenib, sunitinib, and pazopanib. Although these agents show significant preclinical and clinical anti-cancer activity, they prolong overall survival of cancer patients for only months, followed by a restoration of tumor growth and progression. Therefore, there is a clear need to increase our understanding of tumor angiogenesis and the development of resistance. In this review we discuss up-to-date knowledge on mechanisms of tumor angiogenesis, and summarize preclinical and clinical data on existing and potential future anti-angiogenic agents and treatment strategies for Multiple Myeloma (MM) and other hematologic and solid malignancies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Current cancer drug targets - 11(2011), 9, Seite 1005-1024 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Podar, Klaus [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
Gesehen am 23.12.2022 |
|---|
| Umfang: |
20 |
|---|
| doi: |
10.2174/156800911798073113 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
183000512X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 183000512X | ||
| 003 | DE-627 | ||
| 005 | 20230710095252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221223s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/156800911798073113 |2 doi | |
| 035 | |a (DE-627)183000512X | ||
| 035 | |a (DE-599)KXP183000512X | ||
| 035 | |a (OCoLC)1389738557 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Podar, Klaus |e verfasserin |0 (DE-588)1058672169 |0 (DE-627)797396594 |0 (DE-576)414826795 |4 aut | |
| 245 | 1 | 0 | |a Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies |c K. Podar and K.C. Anderson |
| 264 | 1 | |c 2011 | |
| 300 | |a 20 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.12.2022 | ||
| 520 | |a Research on the formation of new blood vessels (angiogenesis) in general and vascular endothelial growth factor (VEGF) in particular is a major focus in biomedicine and has led to the clinical approval of the monoclonal anti- VEGF antibody bevazicumab; and the second-generation multitargeted receptor kinase inhibitors (RTKIs) sorafenib, sunitinib, and pazopanib. Although these agents show significant preclinical and clinical anti-cancer activity, they prolong overall survival of cancer patients for only months, followed by a restoration of tumor growth and progression. Therefore, there is a clear need to increase our understanding of tumor angiogenesis and the development of resistance. In this review we discuss up-to-date knowledge on mechanisms of tumor angiogenesis, and summarize preclinical and clinical data on existing and potential future anti-angiogenic agents and treatment strategies for Multiple Myeloma (MM) and other hematologic and solid malignancies. | ||
| 650 | 4 | |a Angiogenesis Inhibitors | |
| 650 | 4 | |a Antibodies, Monoclonal | |
| 650 | 4 | |a Benzenesulfonates | |
| 650 | 4 | |a Hematologic Neoplasms | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Indoles | |
| 650 | 4 | |a Multiple Myeloma | |
| 650 | 4 | |a Neovascularization, Pathologic | |
| 650 | 4 | |a Niacinamide | |
| 650 | 4 | |a Phenylurea Compounds | |
| 650 | 4 | |a Phthalazines | |
| 650 | 4 | |a Protein Kinase Inhibitors | |
| 650 | 4 | |a Protein-Tyrosine Kinases | |
| 650 | 4 | |a Pyridines | |
| 650 | 4 | |a Pyrroles | |
| 650 | 4 | |a Receptors, Vascular Endothelial Growth Factor | |
| 650 | 4 | |a Signal Transduction | |
| 650 | 4 | |a Sorafenib | |
| 650 | 4 | |a Sunitinib | |
| 650 | 4 | |a Thalidomide | |
| 650 | 4 | |a Vascular Endothelial Growth Factor A | |
| 650 | 4 | |a Wnt Signaling Pathway | |
| 700 | 1 | |a Anderson, Kenneth C. |e verfasserin |0 (DE-588)136657109 |0 (DE-627)585450668 |0 (DE-576)172453887 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d Hilversum [u.a.] : Bentham Science Publ., 2001 |g 11(2011), 9, Seite 1005-1024 |h Online-Ressource |w (DE-627)362755582 |w (DE-600)2099324-9 |w (DE-576)273874209 |x 1873-5576 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2011 |g number:9 |g pages:1005-1024 |g extent:20 |
| 856 | 4 | 0 | |u https://doi.org/10.2174/156800911798073113 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_1200 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 936 | u | w | |d 11 |j 2011 |e 9 |h 1005-1024 |g 20 |
| 951 | |a AR | ||
| 952 | |d 11 |j 2011 |e 9 |h 1005-1024 |g 20 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 4240929245 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 23-12-22 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2011 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_2 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_20 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)148482685X |a Podar, Klaus | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416740783 |a Medizinische Universitätsklinik und Poliklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 | ||